If you have been reading about CJC-1295 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
One person was killed in a Russian missile attack in Sumy Oblast. Russian officials claimed that drones struck energy facilities in Rostov and Voronezh Oblasts. HUR officials claimed that two Su-34s were damaged during a Ukrainian drone strike on the Morozovsk air base in Rostov Oblast, with unconfirmed reports of six pilots killed and 10 troops wounded. Russian President Vladimir Putin claimed that almost 700,000 Russian soldiers were fighting in Ukraine, as on 14 June. The Ukrainian 68th Jaeger Brigade claimed to have destroyed an entire Russian tank company, with eight tanks destroyed and two damaged, plus eight infantry fighting vehicles and two artillery pieces destroyed in the Pokrovsk sector. They also claimed that 242 Russian troops were killed or wounded during fighting in the Pokrovsk direction on 14 June. Russia designated the Georgian National Legion, a foreign volunteer unit fighting for Ukraine, as a terrorist organisation. South Korean Defense Minister Shin Won-sik claimed that North Korea could have sent 4.8 million rounds of artillery ammunition to Russia, for use in Ukraine, as well as "dozens" of ballistic missiles.
The work flow in a hospital laboratory is usually heaviest from 2:00 am to 10:00 am. Nurses and doctors generally have their patients tested at least once a day with common tests such as complete blood counts and chemistry profiles. These orders are typically drawn during a morning run by phlebotomists for results to be available in the patient's charts for the attending physicians to consult during their morning rounds. Another busy time for the lab is after 3:00 pm when private practice physician offices are closing. Couriers will pick up specimens that have been drawn throughout the day and deliver them to the lab. Also, couriers will stop at outpatient drawing centers and pick up specimens. These specimens will be processed in the evening and overnight to ensure results will be available the following day.
The Chilean blob or Chilean monster (Spanish: Monstruo chileno) was a large globster (mass of organic tissue) found on Pinuno Beach in Los Muermos, Chile, in July 2003. It weighed 13 tonnes (14 tons) and measured 12 metres (39 ft) across. The Chilean blob made headlines around the world because biologists were initially unable to identify it and were speculating that it was the remains of some species of giant octopus previously unknown to science. The blob was the subject of a number of conspiracy theories. In June 2004, although no cells remained in the blob, fragments of the DNA found in the blob were found to match that of a sperm whale. The blob was a large mass of adipose tissue, the partial remains of a dead sperm whale. Scientists concluded that the whale had died several months prior and that its carcass had been eaten until only its tough collagen fibres remained.
Sources: en.wikipedia.org
In June 2013, two biosimilar versions (Inflectra and Remsima) were submitted for approval in the European Union, by Hospira and Celltrion Healthcare respectively. Both had a positive opinion from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for sale in the European Union (EU). Celltrion obtained marketing authorization approval (MAA) from 27 EU countries and 3 EEA (European Economic Area) countries by September 2013. Inflectra was approved for use in the European Union in September 2013, and Remsima was approved for use in the European Union in October 2013. In Japan, Celltrion received marketing authorization for Remsima from Japan's Ministry of Health, Labour and Welfare (MHLW) in July 2014. In India, Epirus Biopharmaceuticals obtained approval to produce biosimilar infliximab under the brand name "Infimab" (trail name BOW015). The US Food and Drug Administration (FDA) approved Celltrion/Hospira/Pfizer's Inflectra (infliximab-dyyb) in April 2016. The FDA approved Samsung Bioepis Co., Ltd.'s Renflexis (infliximab-abda) in April 2017. Biogen released another biosimilar, Flixabi, which was approved in Germany, the UK, and the Netherlands. Flixabi was approved for use in the European Union in May 2016. In December 2017, Ixifi (infliximab-qbtx) was approved in the United States. Zessly was approved for use in the European Union in May 2018. In December 2019, Avsola (infliximab-axxq) was approved in the United States. Avsola was approved for medical use in Canada in March 2020.
28 October 2014: Wilkinson A/L Primus, a Malaysian convicted of trafficking heroin in 2008 and sentenced to death in 2009. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced to life imprisonment in 2014 on the grounds that he was intellectually challenged and suffering from depression at the time of the crime. 20 April 2015: Cheong Chun Yin, a Malaysian convicted of trafficking heroin in 2008 and sentenced to death in 2010. He lost his appeal to the Court of Appeal in 2010. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2015 to life imprisonment and 15 strokes of the cane. His boss and accomplice, Pang Siew Fum, was also re-sentenced to life imprisonment on the same day, due to Pang suffering from depression at the time of the crime. 1 July 2015: Kester Ng Wei Ren, a 47-year-old Singaporean caught trafficking in 23.38g of heroin on 12 August 2008. He tried to argue that he only meant to import only 9.92g of heroin while the rest of his drug supply was only meant for his own consumption. Ng was given the mandatory death penalty in 2010 and he also lost his appeal in the same year. After changes to the law took effect in 2013, Ng applied for re-sentencing but he did not meet the criteria to be re-sentenced to life imprisonment. Hence he lost his appeal to be re-sentenced on 1 July 2015 since he was not certified as a courier. He was presumably executed sometime following the loss of his re-sentencing application.
== Further reading == Aird, William C. "Blood Endothelial Cells" in Endothelial Cells In Health and Disease. Boca Raton: Taylor & Francis, 2005. Milosevic, V., Edelmann, R.J., Fosse, J.H., Östman, A., Akslen, L.A. (2022). Molecular Phenotypes of Endothelial Cells in Malignant Tumors. In: Akslen, L.A., Watnick, R.S. (eds) Biomarkers of the Tumor Microenvironment. Springer, Cham. https://doi.org/10.1007/978-3-030-98950-7_3 Stem Cells, Therapeutic Applications by Mariusz Z. Ratajczak Advances in Experimental Medicine and Biology
Sources: en.wikipedia.org
In the human body, the epithelial cells of the small intestine produce citrulline, primarily from glutamine and glutamate, which is secreted into the bloodstream which carries it to the proximal tubule cells of the kidney, which extract the citrulline and convert it to arginine, which is returned to the blood. This means that impaired small bowel or renal function can reduce arginine synthesis and thus create a dietary requirement for arginine. For such a person, arginine would become "essential". Synthesis of arginine from citrulline also occurs at a low level in many other cells, and cellular capacity for arginine synthesis can be markedly increased under circumstances that increase the production of inducible nitric oxide synthase (NOS). This allows citrulline, a byproduct of the NOS-catalyzed production of nitric oxide, to be recycled to arginine in a pathway known as the citrulline to nitric oxide (citrulline-NO) or arginine-citrulline pathway. This is demonstrated by the fact that, in many cell types, nitric oxide synthesis can be supported to some extent by citrulline, and not just by arginine. This recycling is not quantitative, however, because citrulline accumulates in nitric oxide producing cells along with nitrate and nitrite, the stable end-products of nitric oxide breakdown. In bacteria, biosynthesis proceeds via acetylation intermediates. Glutamate is acetylated to N-acetylglutamate and subsequently converted to N-acetylornithine via N-acetylglutamylphosphate and N-acetylglutamate semialdehyde.
Fatty acids that are required for good health but cannot be made in sufficient quantity from other substrates, and therefore must be obtained from food, are called essential fatty acids. There are two series of essential fatty acids: one has a double bond three carbon atoms away from the methyl end; the other has a double bond six carbon atoms away from the methyl end. Humans lack the ability to introduce double bonds in fatty acids beyond carbons 9 and 10, as counted from the carboxylic acid side. Two essential fatty acids are linoleic acid (LA) and alpha-linolenic acid (ALA). These fatty acids are widely distributed in plant oils. The human body has a limited ability to convert ALA into the longer-chain omega-3 fatty acids — eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which can also be obtained from fish. Omega−3 and omega−6 fatty acids are biosynthetic precursors to endocannabinoids with antinociceptive, anxiolytic, and neurogenic properties.
Fishbone is the recording debut of alternative group Fishbone. This six-song EP was released in 1985 and captures the band at the height of their early funk/ska era. The track "Party at Ground Zero" remains one of the band's most popular tracks. The track "V.T.T.L.O.T.F.D.G.F." stands for "Voyage to the Land of the Freeze-Dried Godzilla Farts", as confirmed on the band's website, and imagines a government attempt to convince the public that Hiroshima was actually caused by Godzilla farting.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.